Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Catalyst Pharmaceuticals, Inc.

< Previous 1 2 Next >
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.